Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

Oncogene

Volumn 34, Issue 43, 2015, Pages 5411-5417

  Gao, J ^a   He, Q ^a   Subudhi, S ^a   Aparicio, A ^a   Zurita Saavedra, A ^a   Lee, D H ^a   Jimenez, C ^a   Suarez Almazor, M ^a   Sharma, P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; AUTOIMMUNE THYROIDITIS; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER SURGERY; CD8+ T LYMPHOCYTE; COLITIS; DERMATITIS; DRUG SAFETY; ENDOCRINE DISEASE; ENTEROCOLITIS; ERYTHEMA MULTIFORME; HEMOLYTIC ANEMIA; HEMOPHILIA; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; LEUKOCYTOCLASTIC VASCULITIS; LIVER TOXICITY; LONG TERM SURVIVAL; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MYOCARDITIS; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; REVIEW; RHEUMATIC POLYMYALGIA; SARCOIDOSIS; T LYMPHOCYTE ACTIVATION; TEMPORAL ARTERITIS; TREATMENT RESPONSE; VASCULITIS; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 84945472104     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.5     Document Type: Review

References (42)

1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
2. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
3. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
6. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
7. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116: 1935-1945.
8. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci USA 2008; 105: 3509-3514.
9. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 2013; 49: 24
10. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-712.
11. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 2013; 1291: 1-13.
12. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733-743.
13. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211-212.
14. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
15. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
16. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 501-508.
17. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 509-517.
18. Bristol-Myers Squibb Ipilimumab US prescribing information. http://www.yervoy. com/pdf/pi-yervoy.pdf2013.
19. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophy-sitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28: 593-598.
20. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13: 29-38.
21. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004; 27: 478-479.
22. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008; 8: 9.
23. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011; 22: 991-993.
24. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745.
25. Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009; 32: 203-205.
26. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712-4717.
27. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
28. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-750.
29. Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006; 142: 166-172.
30. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE et al. Enter-ocolitis in patients with cancer after antibody blockade of cytotoxic T-lympho-cyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289.
31. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10: 11.
32. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164: 303-307.
33. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365: 1747-1748.
34. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009; 7: 35.
35. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695-1710.
36. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998; 161: 3347-3356.
37. Ying H, Yang L, Qiao G, Li Z, Zhang L, Yin F et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185: 1375-1378.
38. Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012; 30: 475-477.
39. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105: 20410-20415.
40. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immuno-logic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
41. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15: 2507-2513.
42. Tarhini A. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. Sci-entifica (Cairo) 2013; 2013: 857519.